A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease with limited treatment options in pediatric patients. Liraglutide may be useful for weight management in adolescents with obesity. METHODS: In this randomized, double-blind trial, which consisted of a 56-week treatment period and a 26-week follow-up period, we enrolled adolescents (12 to <18 years of age) with obesity and a poor response to lifestyle therapy alone. Participants were randomly assigned (1:1) to receive either liraglutide (3.0 mg) or placebo subcutaneously once daily, in addition to lifestyle therapy. The primary end point was the change from baseline in the body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) standard-deviation score at week 56. RESULTS: A total of 125 participants were assigned to the liraglutide group and 126 to the placebo group. Liraglutide was superior to placebo with regard to the change from baseline in the BMI standard-deviation score at week 56 (estimated difference, -0.22; 95% confidence interval [CI], -0.37 to -0.08; P = 0.002). A reduction in BMI of at least 5% was observed in 51 of 113 participants in the liraglutide group and in 20 of 105 participants in the placebo group (estimated percentage, 43.3% vs. 18.7%), and a reduction in BMI of at least 10% was observed in 33 and 9, respectively (estimated percentage, 26.1% vs. 8.1%). A greater reduction was observed with liraglutide than with placebo for BMI (estimated difference, -4.64 percentage points) and for body weight (estimated difference, -4.50 kg [for absolute change] and -5.01 percentage points [for relative change]). After discontinuation, a greater increase in the BMI standard-deviation score was observed with liraglutide than with placebo (estimated difference, 0.15; 95% CI, 0.07 to 0.23). More participants in the liraglutide group than in the placebo group had gastrointestinal adverse events (81 of 125 [64.8%] vs. 46 of 126 [36.5%]) and adverse events that led to discontinuation of the trial treatment (13 [10.4%] vs. 0). Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]). One suicide, which occurred in the liraglutide group, was assessed by the investigator as unlikely to be related to the trial treatment. CONCLUSIONS: In adolescents with obesity, the use of liraglutide (3.0 mg) plus lifestyle therapy led to a significantly greater reduction in the BMI standard-deviation score than placebo plus lifestyle therapy. (Funded by Novo Nordisk; NN8022-4180 ClinicalTrials.gov number, NCT02918279.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In adolescents with obesity, liraglutide 3.0 mg reduced BMI by 4.3% over 56 weeks compared to 0.3% with placebo, with early treatment response predicting long-term effectiveness.39”
From GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review (2024) · cites this paper as [39]
In the citing paper
“but modest reduction in main CVD factors over 56 weeks of treatment.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“In a key RCT, there were notable reductions in BMI SDS and higher percentages of participants achieving ≥ 5% and ≥ 10% Weight loss compared to placebo and the BMI standard-deviation score at week 56 (estimated difference, − 0.22; 95% confidence interval [CI], − 0.37 to − 0.08; P = 0.002) [112]”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“Approved by FDA/EMA from age 6.”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [112]
In the citing paper
“The liraglutidetreated group demonstrated a placebo-subtracted weight reduction of 5% (29).”
From New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics (2023) · cites this paper as [29]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Establishing a standard definition for child overweight and obesity worldwide: international survey
Cole, T. J. (2000) · BMJ · doi:10.1136/bmj.320.7244.1240 · Cited by 16,480
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Freedman, D. S., Mei, Z., Srinivasan, S. R., Berenson, G. S., & Dietz, W. H. (2007) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.08.042 · Cited by 1,562
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
le Roux, C. W., Astrup, A., Fujioka, K., Greenway, F., Lau, D. C. W., Van Gaal, L., Ortiz, R. V., Wilding, J. P. H., Skjøth, T. V., Manning, L. S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30069-7 · Cited by 850
Research works printed but not linked: 1
- Frelut M-L De Filippo G. Drug treatment of child and adolescent obesity. In: Frelut M-L ed. ECOG eBook on child and adolescent obesity. 2015 (https://ebook.ecog-obesity.eu/chapter-treatment/drug-treatment-of-child-and-adolescent-obesity/).
Cited by
Items 401–500 of 720
The Economic Value of Treating Pediatric Obesity: Costs Are Not Keeping Up With Efficacy
Ryder, J. R., Lim, F., & Hur, C. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.36337 · Cited by 3
Addressing Obesity Care in Children With Chronic Health Conditions
Kim, A., & Burton, E. T. (2023) · Childhood Obesity · doi:10.1089/chi.2023.0077 · Cited by 2
“…care providers’ perception of obesity has been shown to influence obesity care for these youth, 10,11 and despite several effective and safe medical intervention options for pediatric obesity, 4,12 there remains widespread hesitancy in utilizing these options, particularly for children with CHCs.”
Pediatric Obesity Care via Telemedicine: Expanding the Path Forward—A Review
O’Hara, V. M., Louder, D., Johnston, S. V., Hastey, K., & Browne, N. T. (2023) · Current Obesity Reports · doi:10.1007/s13679-023-00537-w · Cited by 5
Anesthesia considerations for pediatric metabolic and bariatric surgery
Manupipatpong, K., Wayne, C. D., Tobias, J. D., Nafiu, O. O., Michalsky, M. P., & Syed, A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.07.004 · Cited by 4
Michalsky, M. P., Fox, C. K., & Pratt, J. S. A. (2024) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2024.10.018 · Cited by 3
Pediatric Obesity Treatment: Considerations for Diabetes Educators and Clinicians
Laroche, H. H., Fernández, C., Sweeney, B. R., Gillette, M. L. D., & Hampl, S. E. (2024) · Diabetes Spectrum · doi:10.2337/dsi24-0005 · Cited by 3
van den Boom, L., Stuecher, T., & Mader, J. K. (2021) · Clinical Case Reports · doi:10.1002/ccr3.4811 · Cited by 2
Skin and obesity in childhood: an update
Hirschler, V., & Argentine Society of Diabetes, P. 1. (2021) · AIMS Medical Science · doi:10.3934/medsci.2021026 · Cited by 5
Insulin Resistance and Other Mechanisms of Obesity Hypertension
Thaker, V., & Falkner, B. E. (2023) · Springer eBooks · doi:10.1007/978-3-031-06231-5_39 · Cited by 3
Massage for simple obesity: A protocol for systematic review
Pang, Y., Wang, K., Chen, S., Huang, T. J., Zhang, M., Zhang, B., & Yu, J. (2021) · Medicine · doi:10.1097/md.0000000000024336 · Cited by 6
“More than 70% of people who develop obesity before puberty will still show obesity in adulthood.([5,8,9,10]) This finding shows how important it is to control weight and to prevent obesity overall.”
Manejo nutricional e farmacológico da obesidade pediátrica: um tratamento multiprofissional
de Gusmão, A. B., Rocha, S. D. S., Ferreira, B. W. R. C., Santos, A. K. F. D. S., & Macêdo, C. L. (2021) · Research Society and Development · doi:10.33448/rsd-v10i1.11797 · Cited by 3
Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents
Holder, M., Kapellen, T. M., Ziegler, R., Bürger-Büsing, J., Danne, T., Dost, A., Holl, R. W., Holterhus, P., Karges, B., Kordonouri, O., et al. (2022) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1624-3388 · Cited by 6
Pharmacotherapeutic options in pediatric obesity: an urgent call for further research
Bagnes, M. F. G., González, C. D., Hirschler, V., & Girolamo, G. D. (2022) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2050212 · Cited by 4
“0 mg of subcutaneous liraglutide once daily (N = 125) or a placebo plus lifestyle therapy [9].”
Côté, M., Carrière, K., & Alberga, A. S. (2024) · Childhood Obesity · doi:10.1089/chi.2024.0317 · Cited by 3
Pediatric obesity is a complex disease. It is time we start reimbursing for care
Armstrong, S. (2024) · Pediatric Research · doi:10.1038/s41390-024-03201-8 · Cited by 2
“Currently, four medications are FDA-approved for the long-term management of non-monogenic obesity in children aged 12 years and older (liraglutide, 22 semaglutide, 23 phentermine/topiramate, 24 orli-stat 25 ).”
Innovative Care for Children and Adolescents with Severe and/or Genetic Obesity
Schirmer, M., Zorn, S., von Schnurbein, J., & Wabitsch, M. (2025) · Hormone Research in Paediatrics · doi:10.1159/000544177 · Cited by 2
Babiker, A. M. I., Alfaraidi, H., Aljarallah, G. S., Albaraki, J., Alharbi, R., Alsomali, N., Alkhalaf, A., Yenugadhati, N., Juraibah, F. A., & Alwan, I. A. A. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1573109 · Cited by 2
“In a randomized, double-blinded clinical trial in obese adolescents, liraglutide resulted in a statistically signi fi cant reduction in the standard deviation score of BMI, when compared to placebo (12).”
Efectividad de la liraglutida en el tratamiento de la obesidad del adolescente
Pons, M. R., Vilar, M. G., Zurita, C. G., Ferrer, M. E. F., Rodríguez, A. P., & Alonso, C. R. (2025) · Anales de Pediatría · doi:10.1016/j.anpedi.2025.503856 · Cited by 2
Predictors of BMI reduction with phentermine/topiramate in adolescents with obesity
Bensignor, M. O., FREESE, R. L., Rudser, K. D., Kelly, A. S., Kunin‐Batson, A., Gross, A. C., Bramante, C. T., Shih, W., Peterson, C. A., & Fox, C. K. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01821-6 · Cited by 2
“The results of this study describe a heterogeneous response as previously described with other obesity treatments [3 – 5].”
Self-citationRehman, R. (2025) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v14.i3.105731 · Cited by 3
Exploring Challenges With Widespread Use of GLP-1–Based Therapies for Adolescents and Young Adults
Luo, J., Vajravelu, M. E., & Dusetzina, S. B. (2025) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2025.2469 · Cited by 2
Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
Soliman, S., Andrews‐Dickert, R., Ročić, P., & Mitov, M. I. (2025) · Pharmaceuticals · doi:10.3390/ph18101519 · Cited by 3
Tejeji, I., Zeier, T., SMITH, J. A., CHANG, N. T., & Chao, L. C. (2025) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2025-0493 · Cited by 2
“Although higher doses of liraglutide (up to 3 mg) and semaglutide (up to 2.4 mg) have been shown to be e ff ective in weight reduction in adolescents with obesity [21, 22], there is limited data on the e ffi cacy of semaglutide and tirzepatide in youth with type 2 diabetes.”
InfluentialThe Obesity Drug Revolution: New Frontiers in Pharmacotherapy
Manoria, P. C. (2025) · Cureus · doi:10.7759/cureus.96713 · Cited by 7
“A pediatric trial (n=251) showed a 4.64% BMI and 4.5 kg weight reduction, with ≥5% BMI loss in 43.3% vs. 18.7% and ≥10% in 26.1% vs. 8.1% [42].”
InfluentialEffects of incretin drugs on glycemic control and body weight
Levitskaya, A. N., Demidova, T. Y., & Геннадьевна, Л. К. (2025) · FOCUS Endocrinology · doi:10.62751/2713-0177-2025-6-3-07 · Cited by 2
Obesity Hypoventilation Syndrome in Children and Adolescents
Petrongari, D., Filippo, P. D., Cacciatore, F., Ludovico, A. D., Papa, G. F. S., Pillo, S. D., Chiarelli, F., & Attanasi, M. (2026) · Children · doi:10.3390/children13010140 · Cited by 3
“Weight-loss medications, including orlistat and GLP-1 receptor agonists such as liraglutide and semaglutide, have demonstrated efficacy for improving BMI and metabolic outcomes in adolescents [53,66,67].”
Saba, L., Acosta, A. J., Kelly, A. S., & Kumar, S. (2026) · Nutrients · doi:10.3390/nu18020303 · Cited by 3
“Similar variability in BMI response is noted from the randomized trial involving liraglutide, where 43.3% of adolescents achieved ≥ 5% BMI reduction, compared to 26.1% who achieved ≥ 10% reduction in BMI from baseline after 56 weeks of treatment with liraglutide 3 mg [25].”
InfluentialSelf-citationLee, J. J., Bajgain, P., & Lightner, A. L. (2026) · Frontiers in Gastroenterology · doi:10.3389/fgstr.2026.1790420 · Cited by 3
Song, E., Fang, Y., Li, X., Fu, W., He, H., Gao, Z., Tian, X., & Gao, B. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1809416 · Cited by 3
“These typically manifest during the initiation and dose-titration phases and may partially subside over time (77, 139, 140).”
Wan, K., Lei, E. F., Liu, Y., Taddese, A. A., Ip, P. C. T., Torbahn, G., Weghuber, D., Huang, W. Y., & Tam, B. T. (2026) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2026.2248 · Cited by 7
Arterburn, D. E., Curtis, L. H., Toh, S., Bradley, M. C., D’Alessio, D., Duchovny, N., Hines, D. W., Narain, K. D. C., Parekh, A., Skinner, A., et al. (2026) · Annals of Internal Medicine · doi:10.7326/annals-25-05468 · Cited by 3
Cote, M. F., Oza, V. S., & Orlow, S. J. (2026) · Pediatric Dermatology · doi:10.1111/pde.70340 · Cited by 2
Terapia farmacologica dell’obesità: attualità e prospettive future
Vinciguerra, F., & Frittitta, L. (2022) · L Endocrinologo · doi:10.1007/s40619-022-01068-7 · Cited by 2
“Il profilo di sicurezza e di efficacia di liraglutide è stato valutato anche in soggetti di età compresa tra 12 e 18 anni e per questo è stato recentemente approvato per il trattamento dell’obesità anche negli adolescenti [13].”
BackgroundIntegrating semaglutide into obesity management – a primary care perspective
Kyrillos, J. V., SKOLNIK, N., Mukhopadhyay, B., & Pennings, N. J. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2149964 · Cited by 4
“At present, there is only one large, placebo-controlled trial for adolescents using liraglutide [54].”
Anti-Adipogenic and Anti-Obesity Effects of Gongmi Tea and Gongmi So Extract
Jo, S. J., Gong, Y., Jiang, R., Jung, H., & Kim, Y. R. (2023) · Preventive Nutrition and Food Science · doi:10.3746/pnf.2023.28.1.21 · Cited by 2
Baden, C. S., Andersen, J. T., Christensen, M., & Gade, C. (2023) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000067 · Cited by 3
Malíková, J. K., & Lebl, J. (2023) · Česko-slovenská pediatrie · doi:10.55095/cspediatrie2023/024 · Cited by 2
Childhood obesity: An approach to individualized treatment
Collins, P. B., & Brolis, N. V. (2022) · Osteopathic Family Physician · doi:10.33181/13066 · Cited by 2
Fadheel, Q. J. (2024) · Wiadomości Lekarskie · doi:10.36740/wlek202403115 · Cited by 2
An Overview of Modern Strategies for Treating Obesity
Jędrasek, A., Barg, M., Biały-Karbowniczek, J., Bartela, A., & Wojtyła, K. (2024) · Journal of Education Health and Sport · doi:10.12775/jehs.2024.68.49506 · Cited by 2
Versorgungskonzepte für Kinder und Jugendliche mit extremer und/oder genetischer Adipositas
Zorn, S., Schirmer, M., von Schnurbein, J., Brandt, S., Göpel, E., Stein, R., Wiegand, S., Körner, A., Kühnen, P., & Wabitsch, M. (2024) · Adipositas - Ursachen Folgeerkrankungen Therapie · doi:10.1055/a-2292-1830 · Cited by 3
Diagnosis and Management of Hypertension in Adolescents with Obesity
Chhabria, S. M., LeBron, J., Ronis, S. D., & Batt, C. E. (2024) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-024-00740-x · Cited by 7
“GI side effects including nausea and vomiting are common with GLP-1 RAs, particularly at initiation with improvement over time [37, 76].”
BackgroundMethodApproach to the Treatment of Children and Adolescents with Obesity
Hegedus, E., Vidmar, A. P., Mayer, M., Kohli, R., & Kohli, R. (2024) · Gastrointestinal Endoscopy Clinics of North America · doi:10.1016/j.giec.2024.06.004 · Cited by 2
Should young kids take the new anti-obesity drugs? What the research says
Nowogrodzki, J. (2024) · Nature · doi:10.1038/d41586-024-02983-5 · Cited by 3
Novel Insights: A Novel PHIP Variant in a Family with Severe Early-Onset Obesity
Loid, P., Vuorela, N., Aaltonen, K., Kuittinen, J., & Mäkitie, O. (2024) · Hormone Research in Paediatrics · doi:10.1159/000542205 · Cited by 2
“The weight loss in our patient is greater than that observed in a clinical trial of liraglutide treatment in adolescents aged 12 – 18 years [24].”
Sharshova, O. G., Chubarov, T. V., Peterkova, V. A., & Zhdanova, O. A. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-476 · Cited by 2
Chien, T.-E., Chen, P., Chang, K., Hsu, C., Huang, H.-W., Tsai, S., Chen, Y., Chang, C.-H., Yang, H.-R., Tung, Y., et al. (2024) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2025.01.001 · Cited by 2
Can weight loss drugs like Ozempic treat obesity in children?
Lang, K. (2025) · BMJ · doi:10.1136/bmj.q2656 · Cited by 2
Management of adolescent obesity in developing countries: A systematic review
Wiafe, M. A., Ayensu, J., Yeboah, G. B., Eli‐Cophie, D., & Benewaa, A. (2025) · Nutrition and Health · doi:10.1177/02601060251330027 · Cited by 2
“…(liraglutide, sibutra-mine, orlistat, metformin) and/or lifestyle modi fi cation, signi fi cantly reduced the body mass index of adolescents in Sweden, Mexico, Russia, Belgium, United Kingdom and the United States (Berkowitz et al., 2003; Kelly et al., 2020; Kendall et al., 2013; Ozkan et al., 2004).”
Shaping the future of youth-onset type 2 diabetes: a call to action
SHAH, A. S., Kelsey, M. M., Wolf, R. M., & Nadeau, K. J. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.003 · Cited by 2
The treatment of extreme obesity in adolescents and young adults with GLP-1 receptor agonists.
Brandt-Heunemann, S., Schirmer, M., Blüher, S., & Wabitsch, M. (2025) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2024.0250 · Cited by 2
Medikamentöse Adipositastherapie in Deutschland
Blüher, M. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01897-2 · Cited by 4
Incretins for management of obesity and obstructive sleep apnea
Hu, X., Yee, B. J., Phillips, C. L., Chapman, J. L., & Grunstein, R. R. (2025) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2025.2513516 · Cited by 2
“The SCALE Teen study demonstrated similar weight loss efficacy in an adolescent population [49].”
Treating Childhood Obesity: Building and Evaluating Evidence-Based Models of Integrated Care
McSweeney, Z. C., Antonelli, R. C., & Ebbeling, C. B. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf109 · Cited by 4
New Perspectives in Modulating the Entero-Insular Axis in Pediatric Obesity
Dira, L.-M., Marin, L.-M., Popa, S. G., Singer, C.-E., Coşoveanu, C. S., Donoiu, I., & Golli, A. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136143 · Cited by 4
“Liraglutide significantly reduced BMI in teenagers aged 12 to less than 18 years, according to data obtained by Kelly A.S. et al. [86].”
Park, J., Kim, J. W., & Lim, S. (2025) · Annals of Nutrition and Metabolism · doi:10.1159/000547347 · Cited by 4
“Liraglutide 3.0 mg, a GLP-1RA, has been proven effective for weight loss [10] and shows potential benefits for MASLD treat-ment [11].”
InfluentialZhang, J., Xu, H., Dong, Y., Feng, J., & Li, R. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118024 · Cited by 2
GLP-1 and GIP agonists in diabetes and obesity and the rise of dyspepsia
Masulli, M., Tack, J. F., Esposito, G., & Sarnelli, G. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-04117-9 · Cited by 3
Liraglutide and Exercise: A Possible Treatment for Obesity?
Macêdo, A. P. A., Vieira, R. F. L., Brisque, G. D., Abud, G. F., & Pauli, J. R. (2022) · Obesities · doi:10.3390/obesities2030023 · Cited by 3
“The results showed a reduction in body weight compared to the placebo group [28], indicating that this combination of liraglutide and exercise can also benefit younger individuals.”
ResultGLP-1 agonists in treatment of obesity
ORŁOWSKI, W., MERKISZ, K., Zdun, S., Walczak, K., Walczak, P., Nemeczek, S., Grzybowski, J., Marciniak, A., JASKUŁA, K., & Grzywna, N. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.033 · Cited by 2
Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Shin, J., Kim, R., & Kim, H. (2023) · Cardiovascular Prevention and Pharmacotherapy · doi:10.36011/cpp.2023.5.e7 · Cited by 2
THE RELATIONSHIP BETWEEN BODY MASS INDEX AND LIFE SATISFACTION AMONG ADULT RUSSIANS
Gromova, D., & Алексеевна, Х. Н. (2023) · Social Aspects of Population Health · doi:10.21045/2071-5021-2023-69-1-5 · Cited by 5
Żuraw, D., Oleksa, P., Sobczyk, M., & Jasiński, K. (2023) · Prospects in Pharmaceutical Sciences · doi:10.56782/pps.145 · Cited by 2
“Leczenie to powinno być prowadzone przez klinicystów z doświadczeniem w stosowaniu leków wspomagających leczenie otyłości i świadomością możliwości wystąpienia działań niepożądanych [46].”
Vitebskaya, A. V., & Владимировна, П. А. (2023) · Obesity and metabolism · doi:10.14341/omet12922 · Cited by 2
Krnić, N., Šeša, V., Mrzljak, A., & Berković, M. C. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i4.623 · Cited by 2
Liraglutide for overweight and obesity
Das, G. C. (2021) · Practical Diabetes · doi:10.1002/pdi.2313 · Cited by 3
Supplementary drug treatment to reduce weight in adolescents with severe obesity
Rolin, J., Ødegård, R. A., Amundsen, V. V., Köpp, U. M. S., Kokkvoll, A. S., Júlíusson, P. B., & Hjelmesaeth, J. S. (2022) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.22.0540 · Cited by 2
Are GLP-1 drugs really for everybody?
(2024) · Nature Medicine · doi:10.1038/s41591-024-03382-z · Cited by 3
Morrison, K. M., Gunn, E., Schwindt, S., Hu, L., & Tarnopolsky, M. A. (2023) · Clinical Obesity · doi:10.1111/cob.12606 · Cited by 1
Nunes, R. S., de Sousa, R. I. M., dos Santos, V. J. H., Neta, J. A. B., Braga, Í. B. F. C., & Pinto, N. B. (2023) · Temas em Saúde · doi:10.29327/213319.23.3-4 · Cited by 2
Preventive cardiology in pediatrics. A fellow's voice
Hollon, H. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100582 · Cited by 1
“US Food and Drug Administration (FDA)-approved pharmacotherapy options for youth 12 years and older include liraglutide, semaglutide, phentermine, phen-termine/topiramate, and orlistat, which lead to a 4.7 – 16.7 % decrease in BMI depending on the pharmacotherapeutic agent [9 – 11].”
InfluentialPrediabetes in children and adolescents: A ticking bomb!
Gupta, A., Choudhary, N., & Gupta, N. (2024) · World Journal of Clinical Pediatrics · doi:10.5409/wjcp.v13.i2.92127 · Cited by 3
Kharofa, R. Y., Crimmins, N. A., & SHAH, A. S. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.18201 · Cited by 1
Urbanová, V., Mrakava, J., Koubský, K., Aldhoon-Hainerová, I., & Rücklová, K. (2024) · Cor et Vasa · doi:10.33678/cor.2023.100 · Cited by 2
Public health risks of approving drugs for the treatment of childhood obesity in Brazil
Vítolo, M. R., Baratto, P. S., & Deram, S. (2024) · Cadernos de Saúde Pública · doi:10.1590/0102-311xpt031624 · Cited by 2
GLP-1 and GIP analogues in the treatment of obesity
Jasińska-Balwierz, A., Balwierz, R. J., Biernat, P., Makieieva, N., Tomków, M., Cesarz, K., Osowski, M., Dorożyński, B., Skotnicka-Graca, U., & Lipok, J. (2024) · Pediatria i Medycyna Rodzinna · doi:10.15557/pimr.2024.0023 · Cited by 2
Arvate, H. R. (2025) · International Journal of Nutrology · doi:10.54448/ijn25102 · Cited by 1
A Systemic Review of Pharmacological Management of Pediatric Obesity
Gupta, S. K. (2025) · Journal of Pharmacy And Bioallied Sciences · doi:10.4103/jpbs.jpbs_661_24 · Cited by 1
“[1,5,8,12] Restrictions and prospective paths Our systematic review has various limitations, even if the included research offered insightful information.”
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment
Bensignor, M. O., Hsia, D. S., Name, M. A. V., Jastreboff, A. M., & Ryder, J. R. (2025) · Diabetes Care · doi:10.2337/dci25-0031 · Cited by 2
Glucagon-Like Peptide-1-Receptor Agonist Treatment of Obesity: Is It Cost-Effective and Equitable?
Hertzer, L., & Siegel, R. (2025) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2025.114779 · Cited by 1
Mechanisms of glucagon-like-peptide 1 in the brain beyond metabolic effects
Kim, K. S., Park, J. S., & Choi, H. J. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2448320.160 · Cited by 3
“…report that youths with obesity or T2DM (age 18 years) treated with lirglutide or semaglutide along with lifestyle interventions have better metabolic levels and experience greater body weight loss when treated with GLP-1 drugs but showed primary side effects such as nausea and vomiting [93-95].”
Péč, M. J., Jurica, J., Péčová, M., Nagy, N., Focko, B., Miertová, Z., Ferencová, N., Ságová, I., Tonhajzerová, I., Bolek, T., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18091364 · Cited by 4
Dong, J., Liu, M., & Liu, Z. (2025) · Pediatric Research · doi:10.1038/s41390-025-04537-5 · Cited by 3
Are Glucagon-Like Peptide 1 Receptor Agonists and Bariatric Surgery the Answer to Childhood Obesity?
Kumar, S., Olson, O., & Kellogg, T. A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01347-2 · Cited by 3
“One major concern with the use of GLP-1 receptor agonists for treatment of childhood obesity is the weight regain and reversal of improvements in cardiometabolic risk factors that have been observed after discontinuation of these medications [36, 42, 43].”
InfluentialLim, C. Y. S., Loke, K. Y., Varughese, S. M., Lee, Y. S., & Ng, N. B. H. (2025) · Obesity Reviews · doi:10.1111/obr.70072 · Cited by 3
“With the evidence of significant improvements in weight for adolescents receiving either liraglutide or semaglu-tide, these drugs have the potential to improve PCOS features in adolescents [90, 91].”
Hertzer, L., Siegel, R., Kharofa, R. Y., Stackpole, K., & Mahabee‐Gittens, E. M. (2026) · Childhood Obesity · doi:10.1177/21532176251413898 · Cited by 3
Chukir, T., Khalil, A., Suleiman, N., Chagoury, O. L., & Taheri, S. (2026) · Obesity Medicine · doi:10.1016/j.obmed.2026.100684 · Cited by 1
Glucagon-like peptide-1–based pharmacological treatment of obesity: a narrative review
Son, J. W. (2026) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0138 · Cited by 1
Zhang, F., Chen, W., Wang, H., Wu, D., Chen, Z., Cheng, R., Hu, J., Xie, L., Qiu, Y., Zhou, Z., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2026.02.006 · Cited by 3
Obesity in children and adolescents
Berman, C., Kohn, B., & Wilson, D. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.07.004 · Cited by 7
Glucagon-like peptide-1 agonists in children with obesity and type 2 diabetes. an umbrella review
Mirghani, H. O., Albishi, L. A., & Alblewi, S. M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1777907 · Cited by 4
“Hypoglycemia with GLP-1 agonist use is rare and mild (5% and 15-20% when combined with insulin and sulphonylurea); no severe hypoglycemia requiring assistance was reported (11, 46).”
Anker, S. D., Ji, L., Kindel, T. L., Coats, A. J. S., Ojji, D. B., Puente-Barragán, A., Rossing, P. R., Zieroth, S. R., Ahmad, S., Usman, S., et al. (2026) · Journal of the Association of Physicians of India · doi:10.59556/japi.74.1445 · Cited by 1
Sukkar, G., Halabi, M. H., & Faden, Y. H. (2026) · Saudi Journal of Gastroenterology · doi:10.4103/sjg.sjg_455_25 · Cited by 1
“[15,17,18] There was no statistically significant difference between GLP-1 RAs and placebo in the incidence of any adverse event (RR = 1.02, 95% CI [0.95, 1.09], P = 0.65, I 2 = 0%), serious adverse events (RR = 1.06, 95% CI [0.54, 2.08], P = 0.86, I 2 = 0%), or adverse events leading to…”
InfluentialChen, Q., Liu, H., Xu, J., Zhou, Y., & Ma, J. (2026) · BMC Endocrine Disorders · doi:10.1186/s12902-026-02248-4 · Cited by 2
Wang, W., Huang, Y., Guo, X., Cao, Z., Jiang, H., Zheng, Q., Shi, S., Huang, P., Zhou, J., Hu, F., et al. (2026) · Cellular Signalling · doi:10.1016/j.cellsig.2026.112536 · Cited by 1
Childhood Obesity, Medications, and Surgeries
Raghav, S., & Frishman, W. H. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001230 · Cited by 1
Lopez, A., Perl, L., Cohen‐Sela, E., Borger, O., Issan, Y., Interator, H., Azoulay, E., Moran‐Lev, H., Lubetzky, R., Zelber‐Sagi, S., et al. (2026) · Acta Paediatrica · doi:10.1111/apa.70554 · Cited by 3
Silva, C. F. X. C. A., de Souza, B. L., Thomazini, G., Júnior, J., Bisneto, O. I. D. M., Abreu, I. D., Konstantyner, T., & Abreu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70864 · Cited by 2
“The remaining six trials were rated as low risk of bias [22, 23, 25, 27–29].”
Abenavoli, L., Loricchio, A. G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D. L., & Luzza, F. (2026) · Medicina · doi:10.3390/medicina62050986 · Cited by 1
A 10-Year Cost-Effectiveness Analysis of Metabolic and Bariatric Surgery in Adolescents
Rode, J. B., Lim, F., Jenkins, T. M., Ryder, J. R., Inge, T. H., Hur, C., Helmrath, M. A., Courcoulas, A. P., Michalsky, M. P., Sisley, S. R., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.18648 · Cited by 1
Metadata
- Authors
- Kelly, A. S., Auerbach, P., Barrientos-Perez, M., Gies, I., Hale, P. M., Marcus, C., Mastrandrea, L. D., Prabhu, N., & Arslanian, S.
- Affiliations
- University of Minnesota (US)
- From the Department of Pediatrics and Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis (A.S.K.); Novo Nordisk, Søborg, Denmark (P.A.); Pediatric Endocrinology, Hospital Ángeles Puebla, Puebla City, Mexico (M.B.-P.); the Department of Pediatrics, Division of Pediatric Endocrinology, Universitair Ziekenhuis Brussel, Brussels (I.G.); Novo Nordisk, Plainsboro, NJ (P.M.H.); the Division of Pediatrics, Department of Clinical Science Intervention and Technology,...
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-05-28
- Volume
- 382
- Issue
- 22
- Pages
- 2117-2128
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3013213902
- Cited by
- 723
- References
- 34
- Citations by year
- 2026: 133 · 2025: 143 · 2024: 149 · 2023: 109 · 2022: 80 · 2021: 80 · 2020: 26
- FWCI
- 44.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Digital Access to Libraries (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Obesity, Physical Activity, Diet
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- liraglutide, adolescent obesity, childhood obesity, weight management, GLP-1 receptor agonists, lifestyle therapy, body mass index, gastrointestinal adverse effects, drug discontinuation, long-term weight maintenance, drug efficacy
- MeSH terms
- Liraglutide, Healthy Lifestyle, Adolescent, Blood Glucose, Child, Combined Modality Therapy, Double-Blind Method, Female, Gastrointestinal Diseases, Glycated Hemoglobin, Humans, Injections, Subcutaneous, Male, Body Mass Index, Incretins, Pediatric Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.